Does ABIRATERONE Cause Malignant neoplasm progression? 469 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 469 reports of Malignant neoplasm progression have been filed in association with ABIRATERONE (Abiraterone Acetate). This represents 1.4% of all adverse event reports for ABIRATERONE.
469
Reports of Malignant neoplasm progression with ABIRATERONE
1.4%
of all ABIRATERONE reports
81
Deaths
57
Hospitalizations
How Dangerous Is Malignant neoplasm progression From ABIRATERONE?
Of the 469 reports, 81 (17.3%) resulted in death, 57 (12.2%) required hospitalization, and 5 (1.1%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ABIRATERONE. However, 469 reports have been filed with the FAERS database.
What Other Side Effects Does ABIRATERONE Cause?
Death (5,623)
Fatigue (1,928)
Drug ineffective (1,732)
Therapy cessation (1,602)
Prostatic specific antigen increased (1,581)
Disease progression (1,098)
Hospitalisation (1,034)
Hot flush (989)
Asthenia (891)
Off label use (859)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which ABIRATERONE Alternatives Have Lower Malignant neoplasm progression Risk?
ABIRATERONE vs ABIRATERONE\ABIRATERONE
ABIRATERONE vs ABOBOTULINUMTOXINA
ABIRATERONE vs ABRAXANE
ABIRATERONE vs ABROCITINIB
ABIRATERONE vs ACALABRUTINIB